Interleukin-15 receptor blockade in non-human primate kidney transplantation

Transplantation

Volumn 89, Issue 8, 2010, Pages 937-944

  Haustein, Silke ^a   Kwun, Jean ^a,b   Fechner, John ^a   Kayaoglu, Ayhan ^a,c   Faure, Jean Pierre ^a,d   Roenneburg, Drew ^a   Torrealba, Jose ^e   Knechtle, Stuart J ^a,b  

^a University of Wisconsin Health   (United States)

^b EMORY UNIVERSITY   (United States)

^c GAZIOSMANPASA UNIVERSITY   (Turkey)

^d UNIVERSITÉ DE POITIERS   (France)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Interleukin 15; Memory T cells; NK cells; Non human primate; Transplantation

Indexed keywords

CREATININE; HYBRID PROTEIN; HYBRID PROTEIN MUTIL15 FC; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; BLOOD GROUP ABO SYSTEM; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MEGADOSE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; INFECTIOUS COMPLICATION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LABORATORY TEST; LEUKOCYTE; LOW DRUG DOSE; MACACA; MALE; NATURAL KILLER CELL; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77951290369     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d05a58     Document Type: Article

References (29)

1. Pavlakis M, Strehlau J, Lipman M, et al. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996; 62: 543.
2. Strehlau J, Pavlakis M, Lipman M, et al. The intragraft gene activation of markers reflecting T-cell-activation and-cytotoxicity analyzed by quantitative RT-PCR in renal transplantation. Clin Nephrol 1996; 46: 30.
3. Maekawa Y, Tsukumo S, Okada H, et al. Breakdown of peripheral T-cell tolerance by chronic interleukin-15 elevation. Transplantation 2003; 76: 415.
4. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395.
5. Kennedy MK, Park LS. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J Clin Immunol 1996; 16: 134.
6. Mohamadzadeh M, McGuire MJ, Dougherty I, et al. Interleukin-15 expression by human endothelial cells: up-regulation by ultraviolet B and psoralen plus ultraviolet A treatment. Photodermatol Photoimmu-nol Photomed 1996; 12: 17.
7. Weiler M, Rogashev B, Einbinder T, et al. Interleukin-15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells. J Am Soc Nephrol 1998; 9: 1194.
8. + memory T cells by opposing cytokines. Science 2000; 288: 675.
9. Bamford RN, Grant AJ, Burton JD, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. ProcNatlAcadSci USA 1994; 91: 4940.
10. Burton JD, Bamford RN, Peters C, et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl AcadSci USA 1994; 91:4935.
11. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264: 965.
12. Kawamura T, Koka R, Ma A, et al. Differential roles for IL-15R alpha-chain in NK cell development and Ly-49 induction. J Immunol 2003; 171: 5085.
13. + T cells. Proc Natl AcadSci USA 2004; 101: 15154.
14. Sato N, Patel HJ, Waldmann TA, et al. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl AcadSci USA2007; 104:588.
15. Zheng XX, Gao W, Donskoy E, et al. An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation 2006; 81: 109.
16. Ferrari-Lacraz S, Zheng XX, Kim YS, et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001; 167: 3478.
17. Kim YS, Maslinski W, Zheng XX, et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol 1998; 160: 5742.
18. Tagaya Y, Bamford RN, DeFilippis AP, et al. IL-15: Apleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329.
19. Krebs KC, Jin Z, Rudersdorf R, et al. Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques. J Immunol 2005; 175: 5230.
20. Zheng XX, Sanchez-Fueyo A, Sho M, et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19: 503.
21. + intraepithelial T cells. Transplantation 2003; 75: 505.
22. Smith XG, Bolton EM, Ruchatz H, et al. Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival. J Immunol 2000; 165:3444.
23. Ferrari-Lacraz S, Zheng XX, Kim YS, et al. Addition of an IL-15 mutant/FCgamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade. Transplant Proc 2002; 34: 745.
24. Ferrari-Lacraz S, Zheng XX, Fueyo AS, et al. CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein. Transplantation 2006; 82: 1510.
25. Shinozaki M, Hirahashi J, Lebedeva T, et al. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest 2002; 109: 951.
26. Louis S, Audrain M, Cantarovich D, et al. Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. Transplantation 2007; 83: 712.
27. Haanstra KG, Sick EA, Ringers J, et al. No synergy between ATG induction and costimulation blockade induced kidney allograft survival in rhesus monkeys. Transplantation 2006; 82: 1194.
28. Conti F, Frappier J, Dharancy S, et al. Interleukin-15 production during liver allograft rejection in humans. Transplantation 2003; 76: 210.
29. Nemoto T, Takeshita T, Ishii N, et al. Differences in the interleukin-2 (IL-2) receptor system in human and mouse: Alpha chain is required for formation of the functional mouse IL-2 receptor. Eur J Immunol 1995; 25: 3001.